insights_auto
Why is NVAX up 15,80%?
Dive Deeperchevron_right
NVAX:NASDAQ
Novavax Inc
US$12,75
arrow_upward
+15,80%(+1,74) 1D
US$12,69
arrow_downward
-0,49% (-0,063)bedtimeAfter hours
Closed: 9 ຕ.ລ., 16 ໂມງ 0 ນາທີ 00 ວິນາທີ GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NVAX...
Open
US$11,17
High
US$13,04
Low
US$11,03
Mkt. cap
2,10 ຕື້
Avg. vol.
6,76 ລ້ານ
Volume
19,03 ລ້ານ
52-wk high
US$13,38
52-wk low
US$6,20
EPS
US$-1,52
Beta
2,44
Shares outstanding
164,95 ລ້ານ
No. of employees
749
Open
US$11,17
High
US$13,04
Low
US$11,03
Mkt. cap
2,10 ຕື້
Avg. vol.
6,76 ລ້ານ
Volume
19,03 ລ້ານ
52-wk high
US$13,38
52-wk low
US$6,20
EPS
US$-1,52
Beta
2,44
Shares outstanding
164,95 ລ້ານ
No. of employees
749
News stories
From web sources and news partners
Simply Wall Street
·
1 ມື້ກ່ອນ
Novavax (NVAX) Could Be 82% Overvalued On Plague Headlines And Pfizer Deal Focus
24/7 Wall St.
·
2 ມື້ກ່ອນ
Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies
Investing.com
·
2 ມື້ກ່ອນ
Why is Novavax stock surging today?
Yahoo Finance
·
2 ມື້ກ່ອນ
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Profile
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
About Novavax Inc
CEOJohn C. Jacobs
Employees749
Founded1987
HeadquartersGaithersburg, ແມຣີແລນ, ສະຫະລັດ
SectorBiotechnology
Websitenovavax.com